Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021

Sathyavani Subbarao; Lenesha A Warrener; Katja Hoschler; Keith R Perry; Justin Shute; Heather Whitaker; Michelle O’brien; Frances Baawuah; Paul Moss; Helen Parry; Shamez N Ladhani; Mary E Ramsay; Kevin E Brown; Gayatri Amirthalingam

doi:10.2807/1560-7917.ES.2021.26.12.2100329

Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021

Sathyavani Subbarao, Lenesha A Warrener, Katja Hoschler, Keith R Perry, Justin Shute, Heather Whitaker, Michelle O’brien, Frances Baawuah, Paul Moss, Helen Parry, Shamez N Ladhani, Mary E Ramsay, Kevin E Brown, Gayatri Amirthalingam

Research output: Contribution to journal › Article › peer-review

42 Downloads (Pure)

Abstract

Sera were collected from 185 adults aged≥70 years in London to evaluate the immune response to COVID19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in>94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom’s approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.

Original language	English
Article number	2100329
Number of pages	6
Journal	Eurosurveillance
Volume	26
Issue number	12
DOIs	https://doi.org/10.2807/1560-7917.ES.2021.26.12.2100329
Publication status	Published - 25 Mar 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2807/1560-7917.ES.2021.26.12.2100329Licence: Creative Commons: Attribution (CC BY)

SubbaraoS2021RobustFinal published version, 221 KBLicence: Creative Commons: Attribution (CC BY)

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.12.2100329Licence: Creative Commons: Attribution (CC BY)

Cite this

Subbarao, S., Warrener, L. A., Hoschler, K., Perry, K. R., Shute, J., Whitaker, H., O’brien, M., Baawuah, F., Moss, P., Parry, H., Ladhani, S. N., Ramsay, M. E., Brown, K. E., & Amirthalingam, G. (2021). Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Eurosurveillance, 26(12), Article 2100329. https://doi.org/10.2807/1560-7917.ES.2021.26.12.2100329

@article{32fd93e2a13147d3afb7d0f8f510c533,

title = "Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021",

abstract = "Sera were collected from 185 adults aged≥70 years in London to evaluate the immune response to COVID19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in>94% seropositivity after 3 weeks in na{\"i}ve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom{\textquoteright}s approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine. ",

author = "Sathyavani Subbarao and Warrener, {Lenesha A} and Katja Hoschler and Perry, {Keith R} and Justin Shute and Heather Whitaker and Michelle O{\textquoteright}brien and Frances Baawuah and Paul Moss and Helen Parry and Ladhani, {Shamez N} and Ramsay, {Mary E} and Brown, {Kevin E} and Gayatri Amirthalingam",

year = "2021",

month = mar,

day = "25",

doi = "10.2807/1560-7917.ES.2021.26.12.2100329",

language = "English",

volume = "26",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control",

number = "12",

}

Subbarao, S, Warrener, LA, Hoschler, K, Perry, KR, Shute, J, Whitaker, H, O’brien, M, Baawuah, F, Moss, P , Parry, H, Ladhani, SN, Ramsay, ME, Brown, KE & Amirthalingam, G 2021, 'Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021', Eurosurveillance, vol. 26, no. 12, 2100329. https://doi.org/10.2807/1560-7917.ES.2021.26.12.2100329

TY - JOUR

T1 - Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021

AU - Subbarao, Sathyavani

AU - Warrener, Lenesha A

AU - Hoschler, Katja

AU - Perry, Keith R

AU - Shute, Justin

AU - Whitaker, Heather

AU - O’brien, Michelle

AU - Baawuah, Frances

AU - Moss, Paul

AU - Parry, Helen

AU - Ladhani, Shamez N

AU - Ramsay, Mary E

AU - Brown, Kevin E

AU - Amirthalingam, Gayatri

PY - 2021/3/25

Y1 - 2021/3/25

N2 - Sera were collected from 185 adults aged≥70 years in London to evaluate the immune response to COVID19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in>94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom’s approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.

AB - Sera were collected from 185 adults aged≥70 years in London to evaluate the immune response to COVID19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in>94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom’s approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.

U2 - 10.2807/1560-7917.ES.2021.26.12.2100329

DO - 10.2807/1560-7917.ES.2021.26.12.2100329

M3 - Article

SN - 1025-496X

VL - 26

JO - Eurosurveillance

JF - Eurosurveillance

IS - 12

M1 - 2100329

ER -

Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this